Next, clinical correlations between dynamics of immune checkpoints and clinical outcomes were seen by monitoring the expression of PD-1, PD-L1, and PD-L2 in each MDS patient. The gene discussed is PDCD1LG2; the disease is myelodysplastic syndrome.